Insider Cluster (2 insiders) ·Filed Aug 21, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago
Insider cluster: 2 insiders, $598K total
Actionable Insight • Neutral

Insider sales are trivial in size and involve non-C-suite executives — no actionable signal. Monitor for any material corporate events (e.g., pipeline readouts, regulatory decisions) that could drive the stock, but this cluster alone does not warrant a trade.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
TAK ▲ +3.91% at T+20d
NEUTRAL call ✓ call won +3.91% · α vs SPY +4.43% · entry $18.18 → $18.89
Next anchor: T+60d in 6w
Latest observation: T+27 -1.09% FF3 residual α
Entry anchored
Aug 20, 04:00 PM ET
via 1-min bar
T+1d
+0.33%
call +0.33% · α +0.62%
$18.24
settled 6w ago
T+5d
-0.83%
call -0.83% · α -1.30%
$18.03
settled 5w ago
T+20d
+3.91%
call +3.91% · α +4.43%
$18.89
settled 14d ago
T+60d
—
call — · α —
—
in 6w

Price Chart

Loading chart...

Executive Summary

Two Takeda insiders — the President of R&D and the Chief Human Resources Officer — sold a combined $598K in open-market sales over two days. The total is ~0.001% of the $57.3B market cap, well below the 0.1% materiality threshold, and both sales are likely routine portfolio diversification or tax-related. No bullish or bearish signal from this cluster.

Key Financial Metrics

Direction
selling
Total Value
$598.0K
Insiders
2

Key Facts

  • President of R&D sold 19,651 shares for $363K on 2026-08-19
  • Chief Human Resources Officer sold 12,980 shares for $235K on 2026-08-18
  • Total cluster value of $598K represents ~0.001% of Takeda's $57.3B market cap
  • Both transactions are open-market sales with no insider purchases in the window

Financial Impact

Total insider sales of $598K, immaterial relative to $57.3B market cap

insider_holdings

Risk Factors

  • Insider sales could be misinterpreted as bearish by retail traders
  • No insider buying to offset the selling signal

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TAK-1787378795017
13 reports for TAK
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TAK — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$18.60 $18.89▲ +1.56%▲ +1.45%$17.86 (−3.98%)
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.18 $18.03▼ −0.83%▼ −1.30%$17.86 (−1.76%)
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.34 $18.23▼ −0.60%▼ −0.21%$17.86 (−2.62%)
Aug 14, 2026
7w ago
Court Ruling
NEUTRAL ★ 4/10
$17.63 $18.18▲ +3.12%▲ +4.49%$17.86 (+1.30%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Jul 9, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.61 $16.73▲ +0.72%▲ +0.85%$17.86 (+7.53%)
Jul 8, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.75 $16.39▼ −2.15%▼ −3.01%$17.86 (+6.63%)
Jul 6, 2026
12w ago
3
NEUTRAL ★ 2/10
$16.89 $16.56▼ −1.95%▼ −2.44%$17.86 (+5.74%)
Jun 29, 2026
13w ago
6-K
NEUTRAL ★ 2/10
$15.98 $16.89▲ +5.69%▲ +4.31%$17.86 (+11.76%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 22, 2026